Vilazodone lacks proarrhythmogenic potential in healthy participants: A thorough ECG study

International Journal of Clinical Pharmacology and Therapeutics

Volumn 51, Issue 6, 2013, Pages 456-465

  Edwards, John ^a   Sperry, Vasi ^a,e   Adams, Marijke H ^b   Gallipoli, Susan ^a,f   Thorn, Michael D ^c   Longstreth, James ^d   Boinpally, Ramesh ^a  

^a FOREST RESEARCH INSTITUTE   (United States)

^b MH Adams and Associates Inc   (United States)

^c StatWorks Inc   (United States)

^d Longstreth and Associates Inc   (United States)

^e PGxHealth LLC   (United States)

^f Clinical Data Inc   (United States)

Author keywords

Major depressive disorder; Serotonin; Thorough QT QTc study; Vilazodone

Indexed keywords

MOXIFLOXACIN; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; VILAZODONE;

ADULT; AREA UNDER THE CURVE; ARRHYTHMOGENESIS; ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; HEADACHE; HEART RATE; HEART REPOLARIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NIGHTMARE; PARALLEL DESIGN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PR INTERVAL; QRS COMPLEX; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; TABLET FORMULATION; UNSPECIFIED SIDE EFFECT; VOMITING;

ADOLESCENT; ADULT; ARRHYTHMIAS, CARDIAC; BENZOFURANS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; INDOLES; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PIPERAZINES; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN UPTAKE INHIBITORS; YOUNG ADULT;

EID: 84878804774     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201826     Document Type: Article

References (21)

1. Centers for Disease Control and Prevention. QuickStats: Prevalence of Current Depression* Among Persons Aged ≥ 12 Years, by Age Group and Sex - United States, National Health and Nutrition Examination Survey, 2007-2010. Morbidity and Mortality Weekly Report. 2012; 60: 1747.
2. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005; 62: 593-602. doi:10.1001/archpsyc.62.6.593 PubMed (Pubitemid 40973434)
3. Peretti S, Judge R, Hindmarch I. Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl. 2000; 403 (s403): 17-25. doi:10.1111/j.1600-0447.2000. tb10944.x PubMed
4. Thase ME. Are SNRIs more effective than SSRIs? A review of the current state of the controversy. Psychopharmacol Bull. 2008; 41: 58-85. PubMed
5. Dawson LA, Watson JM. Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders. CNS Neurosci Ther. 2009; 15: 107-117. doi:10.1111/j.1755-5949.2008.00067.x PubMed
6. Hughes ZA, Starr KR, Langmead CJ, Hill M, Bartoszyk GD, Hagan JJ, Middlemiss DN, Dawson LA. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur J Pharmacol. 2005; 510: 49-57. doi:10.1016/j.ejphar.2005.01.018 PubMed (Pubitemid 40312389)
7. Khan A, Cutler AJ, Kajdasz DK, Gallipoli S, Athanasiou M, Robinson DS, Whalen H, Reed CR. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry. 2011; 72: 441-447. doi:10.4088/ JCP.10m06596 PubMed
8. Rickels K, Athanasiou M, Robinson DS, Gibertini M, Whalen H, Reed CR. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, doubleblind, placebo-controlled trial. J Clin Psychiatry. 2009; 70: 326-333. doi:10.4088/JCP.08m04637 PubMed
9. Robinson DS, Kajdasz DK, Gallipoli S, Whalen H, Wamil A, Reed CR. A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder. J Clin Psychopharmacol. 2011; 31: 643-646. PubMed
10. Sala M, Coppa F, Cappucciati C, Brambilla P, d'Allio G, Caverzasi E, Barale F, De Ferrari GM. Antidepressants: their effects on cardiac channels, QT prolongation and Torsade de Pointes. Curr Opin Investig Drugs. 2006; 7: 256-263. PubMed
11. van Noord C, Straus SM, Sturkenboom MC, Hofman A, Aarnoudse AJ, Bagnardi V, Kors JA, Newton- Cheh C, Witteman JC, Stricker BH. Psychotropic drugs associated with corrected QT interval prolongation. J Clin Psychopharmacol. 2009; 29: 9-15. doi:10.1097/JCP.0b013e318191c6a8 PubMed
12. Zemrak WR, Kenna GA. Association of antipsychotic and antidepressant drugs with Q-T interval prolongation. Am J Health Syst Pharm. 2008; 65: 1029-1038. doi:10.2146/ajhp070279 PubMed (Pubitemid 351768736)
13. Arizona Center for Education and Research on Therapeutics. QT Drug Lists by Risk Groups 2012. At: http://www.azcert.org/medical-pros/drug-lists/drug- lists.cfm. Accessed May 16, 2012.
14. Roden DM, Yang T. Protecting the heart against arrhythmias: potassium current physiology and repolarization reserve. Circulation. 2005; 112: 1376-1378. doi:10.1161/CIRCULATIONAHA.105.562777 PubMed (Pubitemid 41291759)
15. Fermini B, Fossa AA. The impact of drug-induced QT interval prolongation on drug discovery and development. Nat Rev Drug Discov. 2003; 2: 439-447. doi:10.1038/nrd1108 PubMed (Pubitemid 37361725)
16. Darpo B. The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance. Br J Pharmacol. 2010; 159: 49-57. doi:10.1111/j.1476-5381. 2009.00487.x PubMed
17. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline E14. The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. At: http://www.ich.org/ fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E14/E14-Guideline. pdf. Accessed May 16, 2012.
18. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline E6(R1). Guideline for Good Clinical Practice. At: http://www.ich.org/ products/guidelines/efficacy/article/efficacy-guidelines.html. Accessed May 16, 2012.
19. Batchvarov VN, Ghuran A, Smetana P, Hnatkova K, Harries M, Dilaveris P, Camm AJ, Malik M. QT-RR relationship in healthy subjects exhibits substantial intersubject variability and high intrasubject stability. Am J Physiol Heart Circ Physiol. 2002; 282: H2356-H2363. PubMed (Pubitemid 34663047)
20. Malik M, Färbom P, Batchvarov V, Hnatkova K, Camm AJ. Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart. 2002; 87: 220-228. doi:10.1136/heart.87.3.220 PubMed (Pubitemid 34177674)
21. Viibryd (package insert). New York, NY: Forest Laboratories Inc; 2011.